SOHM Announces Business Outlook for 2024
-- Branded Generics (off-patent prescription pharmaceuticals)
- CHINO HILLS, Calif., Dec. 05, 2023 (GLOBE NEWSWIRE) -- via IBN -- SOHM, Inc. (OTC PINK: SHMN) (the “Company”), a pharmaceutical, nutraceutical and cosmeceutical Company that manufactures and markets generic drugs covering numerous treatment categories, announced:
SOHM Announces Business Outlook for 2024 for each of its Business Units. - SOHM, Inc. is organized into the following business units:
For each business unit, the Company will provide a 2024 outlook along with relevant business unit-specific status on: market backgrounds, business strategy, business model, branding strategy, sales channels, and commercial status. - The Company anticipates deriving 50-55% of its revenues from the branded generic business division during the year 2024.
- Interim scientific results from R&D will be available during SOHM’s participation at:
April 2024: American Association of Cancer Research 2024 in San Diego, CA
May 2024: SynbioBeta 2024 in San Jose, CA
The Company is planning to commence its first ABBIE kit manufacturing within 2024.